I 
115TH CONGRESS 
2D SESSION 
H. R. 5353 
To amend the Public Health Service Act to reauthorize and expand a program 
of surveillance and education, carried out by the Centers for Disease 
Control and Prevention, regarding infections associated with injection 
drug use. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 20, 2018 
Mr. LANCE (for himself, Mr. KENNEDY, Mr. COLLINS of New York, Ms. 
ESHOO, Mr. BARTON, and Ms. MATSUI) introduced the following bill; 
which was referred to the Committee on Energy and Commerce 
A BILL 
To amend the Public Health Service Act to reauthorize and 
expand a program of surveillance and education, carried 
out by the Centers for Disease Control and Prevention, 
regarding infections associated with injection drug use. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Eliminating Opioid Re-
lated Infectious Diseases Act of 2018’’. 
VerDate Sep 11 2014 
22:45 Mar 27, 2018
Jkt 079200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H5353.IH
H5353
amozie on DSK30RV082PROD with BILLS
SEC. 2. REAUTHORIZATION AND EXPANSION OF PROGRAM 
OF 
SURVEILLANCE 
AND 
EDUCATION 
RE-
GARDING INFECTIONS ASSOCIATED WITH IN-
JECTION DRUG USE. 
Section 317N of the Public Health Service Act (42 
U.S.C. 247b–15) is amended to read as follows: 
‘‘SEC. 317N. SURVEILLANCE AND EDUCATION REGARDING 
INFECTIONS ASSOCIATED WITH INJECTION 
DRUG USE. 
‘‘(a) IN GENERAL.—The Secretary, acting through 
the Director of the Centers for Disease Control and Pre-
vention, may (directly and through grants to public and 
nonprofit private entities) provide for programs to carry 
out the following activities: 
‘‘(1) To cooperate with the States in imple-
menting a surveillance system to determine the inci-
dence of infections associated with injection drug use 
and to assist the States in determining the preva-
lence of such infections, including the reporting of 
chronic hepatitis C virus and human immuno-
deficiency virus cases. 
‘‘(2) To identify, counsel, and offer testing to 
individuals who are at risk of infections as a result 
of injection drug use, receiving blood transfusions 
prior to July 1992, or other risk factors. 
VerDate Sep 11 2014 
22:45 Mar 27, 2018
Jkt 079200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H5353.IH
H5353
amozie on DSK30RV082PROD with BILLS
‘‘(3) To provide appropriate referrals for coun-
seling, testing, and medical treatment of individuals 
identified under paragraph (2) and to ensure, to the 
extent practicable, the provision of appropriate fol-
low-up services. 
‘‘(4) To develop and disseminate public infor-
mation and education programs for the detection 
and control of infections associated with injection 
drug use, with priority given to high-risk populations 
as determined by the Secretary. 
‘‘(5) To improve the education, training, and 
skills of health professionals in the detection and 
control of infections associated with injection drug 
use, with priority given to substance use disorder 
treatment providers, pediatricians, other primary 
care providers, and obstetrician-gynecologists. 
‘‘(b) LABORATORY
PROCEDURES.—The Secretary 
may (directly and through grants to public and nonprofit 
private entities) carry out programs to provide for im-
provements in the quality of clinical-laboratory procedures 
regarding infections associated with injection drug use. 
‘‘(c) DEFINITIONS.—In this section, the term ‘injec-
tion drug use’ means— 
VerDate Sep 11 2014 
22:45 Mar 27, 2018
Jkt 079200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H5353.IH
H5353
amozie on DSK30RV082PROD with BILLS
‘‘(1) intravenous administration of a substance 
in schedule I under section 202 of the Controlled 
Substances Act; 
‘‘(2) intravenous administration of a substance 
in schedule II, III, IV, or V under section 202 of the 
Controlled Substances Act that has not been ap-
proved for intravenous use under— 
‘‘(A) section 505 of the Federal Food, 
Drug and Cosmetic Act; or 
‘‘(B) section 351 of the Public Health 
Service Act; or 
‘‘(3) intravenous administration of a substance 
in schedule II, III, IV, or V under section 202 of the 
Controlled Substances Act that has not been pre-
scribed to the person using the substance. 
‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—For the 
purpose of carrying out this section, there are authorized 
to be appropriated $40,000,000 for each of the fiscal years 
2019 through 2023.’’. 
Æ 
VerDate Sep 11 2014 
22:45 Mar 27, 2018
Jkt 079200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\H5353.IH
H5353
amozie on DSK30RV082PROD with BILLS